Trial Radar IA

Discutiamo ed esploriamo gli studi clinici con Chugai Pharmaceutical come promotore principale o collaboratore.

Posso aiutarti a capire le condizioni di salute, i trattamenti o a trovare studi clinici vicini.
Il nostro strumento di ricerca supporta solo l'inglese. Per la ricerca e la discussione in altre lingue, usa Trial Radar IA sopra o seleziona i filtri per condizione medica e luogo (qui sotto).
43 studi clinici
 
Tipo
Procedura, Farmaco, Integratore Alimentare
×
 
Titolo dello studio
Stato
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A (ZEBRHA 2) NCT07416604
Non ancora in arruolamento
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A (ZEBRHA 1) NCT07416526
Non ancora in arruolamento
Study of DONQ52 in Active Celiac Disease NCT07239336
In arruolamento
A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER NCT07107490
In arruolamento
Study of AUBE00 in Patients With Solid Tumors NCT07030959
In arruolamento
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-2) NCT06819891
In arruolamento
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) NCT06819878
In arruolamento
Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC (INDUCE) NCT06793553
In arruolamento
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Krascendo 2) NCT06793215
In arruolamento
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) NCT06723106
Arruolamento su invito
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-1) NCT06589986
Attivo, non in arruolamento
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (Krascendo 1) NCT06497556
Attivo, non in arruolamento
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) NCT06371417
In arruolamento
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors NCT05907980
In arruolamento
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) (SKYSCRAPER-14) NCT05904886
Attivo, non in arruolamento
Uno studio per valutare la sicurezza, la farmacocinetica e l'attività di RO7496353 in combinazione con un inibitore del checkpoint con o senza chemioterapia standard di cura in partecipanti con tumori solidi localmente avanzati o metastatici; sottostudio sul carcinoma uroteliale in associazione allo studio RO7496353 GO44010 NCT05867121
Attivo, non in arruolamento
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors NCT05735366
Completato
Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial) NCT05679570
Attivo, non in arruolamento
Uno studio per valutare l'efficacia, la sicurezza, la farmacocinetica (PK) e la farmacodinamica (PD) di satralizumab nei partecipanti con encefalite anti-recettore N-metil-D-aspartico (NMDAR) o anti-leucine-rich glioma-inactivated 1 (LGI1) (Cielo) NCT05503264
In arruolamento
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) NCT05494619
Ritirato
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients NCT05425446
Completato
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (Meteoroid) NCT05271409
In arruolamento
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention (SAkuraBonsai) NCT05269667
TerminatoRisultati pubblicati
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma NCT05022927
Attivo, non in arruolamento
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). NCT05012618
Terminato
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis NCT04963270
TerminatoRisultati pubblicati
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-p) NCT04958265
Attivo, non in arruolamento
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-a) NCT04861259
Attivo, non in arruolamento
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO) NCT04740931
CompletatoRisultati pubblicati
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON) NCT04740905
CompletatoRisultati pubblicati
A Phase III Study of Bevacizumab and Paclitaxel in Combination with Atezolizumab As a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (AMBITION) NCT04732598
Attivo, non in arruolamento
A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer NCT04708847
Completato
Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371 NCT04649216
Completato
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). NCT04511845
Attivo, non in arruolamento
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors (COMMODORE 2) NCT04434092
Attivo, non in arruolamentoRisultati pubblicati
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (COMMODORE 1) NCT04432584
Attivo, non in arruolamento
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03) NCT04338269
TerminatoRisultati pubblicati
A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism NCT04209179
Terminato
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) NCT03726879
CompletatoRisultati pubblicati
Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria (COMPOSER) NCT03157635
Attivo, non in arruolamento
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN 4) NCT03020160
CompletatoRisultati pubblicati
A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis NCT02965053
Completato
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3) NCT02847637
CompletatoRisultati pubblicati